OBJECTIVE: The live-attenuated oral polio vaccine (OPV) will be no longer used when wild poliovirus (WPV) eliminating in worldwide, according to GPEI (the Global Polio Eradication Initiative) Reports. It is planning to replace OPV by Sabin-based inactivated poliovirus vaccine (sIPV) in developing countries, with purpose of reducing of the economic burden and maintaining of the appropriate antibody levels in population. It studied serial fractional doses immunized by intradermal injection (ID) in rats, to reduce consume of antigen and financial burden, maintaining sufficient immunogenicity; Methods: Study groups were divided in 4 groups of dose gradient, which were one-tenth (1/10), one-fifth (1/5), one-third (1/3) and one-full dose (1/1), according to the volume of distribution taken from the same batch of vaccine (sIPV). Wistar rats were injected intradermally with the needle and syringe sing the mantoux technique taken once month for 3 times. It was used as positive control that intramuscular inoculation (IM) was injected with one-full dose (1/1) with same batch of sIPV. PBS was used as negative control. Blood samples were collected via tail vein. After 30 d with 3 round of immunization, it analyzed the changes of neutralization antibody titers in the each group by each immunization program end; Results: The results of seroconversion had positive correlation with different doses in ID groups. The higher concentration of D-antigen (D-Ag) could conduct higher seroconversion. Furthermore, different types of viruses had different seroconversion trend. It showed that the geometric mean titers (GMTs) of each fractional-dose ID groups increased by higher concentration of D-Ag, and it got significant lower than the full-dose IM group. At 90th days of immunization, the GMTs for each poliovirus subtypes of fractional doses were almost higher than 1:8, implied that it could be meaning positive seroprotection titer for polio vaccine types, according to WHO suggestion; Conclusions: The fractional dose with one-fifth (1/5) could be used by intradermal injection to prevent poliovirus infection, if there were more human clinical detail research consistent with this findings in rats.
OBJECTIVE: The live-attenuated oral polio vaccine (OPV) will be no longer used when wild poliovirus (WPV) eliminating in worldwide, according to GPEI (the Global Polio Eradication Initiative) Reports. It is planning to replace OPV by Sabin-based inactivated poliovirus vaccine (sIPV) in developing countries, with purpose of reducing of the economic burden and maintaining of the appropriate antibody levels in population. It studied serial fractional doses immunized by intradermal injection (ID) in rats, to reduce consume of antigen and financial burden, maintaining sufficient immunogenicity; Methods: Study groups were divided in 4 groups of dose gradient, which were one-tenth (1/10), one-fifth (1/5), one-third (1/3) and one-full dose (1/1), according to the volume of distribution taken from the same batch of vaccine (sIPV). Wistar rats were injected intradermally with the needle and syringe sing the mantoux technique taken once month for 3 times. It was used as positive control that intramuscular inoculation (IM) was injected with one-full dose (1/1) with same batch of sIPV. PBS was used as negative control. Blood samples were collected via tail vein. After 30 d with 3 round of immunization, it analyzed the changes of neutralization antibody titers in the each group by each immunization program end; Results: The results of seroconversion had positive correlation with different doses in ID groups. The higher concentration of D-antigen (D-Ag) could conduct higher seroconversion. Furthermore, different types of viruses had different seroconversion trend. It showed that the geometric mean titers (GMTs) of each fractional-dose ID groups increased by higher concentration of D-Ag, and it got significant lower than the full-dose IM group. At 90th days of immunization, the GMTs for each poliovirus subtypes of fractional doses were almost higher than 1:8, implied that it could be meaning positive seroprotection titer for polio vaccine types, according to WHO suggestion; Conclusions: The fractional dose with one-fifth (1/5) could be used by intradermal injection to prevent poliovirus infection, if there were more human clinical detail research consistent with this findings in rats.
Authors: R Bruce Aylward; Roland W Sutter; Steve L Cochi; Kimberly M Thompson; Hamid Jafari; David Heymann Journal: Risk Anal Date: 2006-12 Impact factor: 4.000
Authors: Marie Le Borgne; Nathalie Etchart; Anne Goubier; Sergio A Lira; Jean Claude Sirard; Nico van Rooijen; Christophe Caux; Smina Aït-Yahia; Alain Vicari; Dominique Kaiserlian; Bertrand Dubois Journal: Immunity Date: 2006-02 Impact factor: 31.745
Authors: Koen van der Maaden; Sebastiaan J Trietsch; Heleen Kraan; Eleni Maria Varypataki; Stefan Romeijn; Raphäel Zwier; Heiko J van der Linden; Gideon Kersten; Thomas Hankemeier; Wim Jiskoot; Joke Bouwstra Journal: Pharm Res Date: 2014-01-28 Impact factor: 4.200
Authors: Sonia Resik; Alina Tejeda; Roland W Sutter; Manuel Diaz; Luis Sarmiento; Nilda Alemañi; Gloria Garcia; Magilé Fonseca; Lai Heng Hung; Anna-Lea Kahn; Anthony Burton; J Mauricio Landaverde; R Bruce Aylward Journal: N Engl J Med Date: 2013-01-31 Impact factor: 91.245
Authors: Yvonne E Thomassen; Aart G van 't Oever; Monique G C T van Oijen; René H Wijffels; Leo A van der Pol; Wilfried A M Bakker Journal: PLoS One Date: 2013-12-12 Impact factor: 3.240